Oct. 4 at 6:51 PM
I'm interested in hearing some thoughtful opinions regarding the current risk-fact of
$HRTX
This is a very specific question.
I'm not asking about the risk:reward ratio. I understand that depending on the timeframe, overall HRTX has been in a downward trajectory.
(However, we could also be at a modest pivot point IMO.)
What I'm trying to determine is whether HRTX is currently in the position where it is very unlikely that it could fall greater than -20% to -25% of its current value, which closed at
$1.32/share on Friday.
Back in Nov. 2023, HRTX reached a 52-wk low of 54¢. There were cash flow and solvency fears, poor Zynrelef sales, and dilution. Mgt. change occurred, but I also see via comments here that investors have not been pleased w/ new mgmt.
Question Synopsis: Is HRTX likely to be (a) near its low given the improbably of any surprise negative catalyst (are there any that could pop up?) and (b) despite high appearing trading vol. of 2M/day, the actual real volume from Retail investors could be as low as 10% ... however, if Quants drop the price or if a large institutional fund exits wouldn't someone or some entity buy?
Do the recent insider buys, with significant purchases by insiders including Adam Morgan and Rubric Capital Management, totaling over
$6.2 million in the last three months as of October 2025 establish any pricing floor for retail investors?
Thoughts?
Thanks!
